Danish Prostate Cancer Consortium Study-1

Launched by AARHUS UNIVERSITY HOSPITAL · Mar 1, 2023

Keywords

ClinConnect Summary

The Danish Prostate Cancer Consortium Study-1 is a clinical trial designed to test a new urine test called uCaP, which looks for certain markers in urine that may indicate prostate cancer. The main goal is to see if uCaP is better than the current standard blood test, PSA, at identifying men who should get an MRI scan of the prostate. The study will involve 2,500 men from three hospitals in Denmark, and researchers believe that uCaP could be more than 20% better at finding cancers that need treatment. This means it could help doctors decide who really needs an MRI, which would reduce unnecessary scans and treatments for less serious cases of prostate cancer while still catching the aggressive ones in time.

To be eligible for this study, participants must be men aged 18 or older who are referred for an MRI because their doctor suspects prostate cancer. They should speak and understand Danish. However, men who have already been diagnosed with prostate cancer or other related cancers, have certain medical conditions that prevent them from getting an MRI, or have extremely high PSA levels are not eligible. If you join the study, you will be helping researchers improve how prostate cancer is diagnosed and treated, which could make a big difference for many men in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • Understand oral and written Danish.
• • Referred to MRI (multi or bi-parametric) due to suspicion of PC at AUH, OUH, or HGH.
• Exclusion Criteria:
• • Previously diagnosed with PC or other urogenital cancers.
• • Has one or more contraindications for MRI.
• • Have had gender reassignment treatment.
• • Blood PSA levels \> 20 μg/l.